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Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer
(PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2
mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort.
Methods: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB)
in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men
with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of
PSA or PSAV.
Results: 1634 participants had X3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA
43.0 ngml l, PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for
predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between
BRCA status and last PSA before biopsy (P¼ 0.031) and BRCA2 status and PSAV (P¼ 0.024). However, PSAV was not predictive of
biopsy outcome in BRCA2 carriers.
Conclusions: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids
decision-making for BRCA carriers over absolute PSA value alone.
Men with germline mutations in BRCA2 have an increased risk of
prostate cancer (PrCa), estimated at 2.5–8.6 fold increased risk for
BRCA2 mutation carriers (Breast Cancer Linkage Consortium,
1999; van Asperen et al, 2005; Kote-Jarai et al, 2011). There
remains debate about whether there is an increased risk of PrCa
associated with BRCA1 mutations, with some studies reporting no
increased risk to those reporting a 1.8–3.75 fold increased risk
(Thompson et al, 2002; Leongamornlert et al, 2012; Moran et al,
2012). A number of studies have reported that BRCA2 mutation
carriers have more aggressive disease, suggested by their younger
age at diagnosis, higher rates of lymph node involvement and
distant metastasis at diagnosis, and higher mortality rates
compared with non-carriers (Tryggvado´ttir et al, 2007; Mitra
et al, 2008; Edwards et al, 2010; Gallagher et al, 2010; Thorne et al,
2011; Castro et al, 2013). There is increasing evidence that BRCA1
mutation carriers may also harbour more aggressive disease (Giusti
et al, 2003; Gallagher et al, 2010; Castro et al, 2013). Furthermore,
BRCA2-mutant localised prostate cancer demonstrates increased
genomic instability and a mutational profile that more closely
resembles metastastic than localised disease, therefore supporting
early detection in this at risk patient population (Taylor et al,
2017).
General population prostate specific antigen (PSA) screening
remains controversial due to an unclear balance of benefits, in
terms of mortality reduction when compared to harms such as
overdiagnosis and overtreatment. However, many expert groups
continue to recommend PrCa screening with particular attention
towards men with risk factors based on family history, genetics
and/or race (Roobol et al, 2013; Eeles et al, 2014; Mikropoulos et al,
2014; Murphy et al, 2014).
It has previously been suggested that the rate of PSA change
over time, or PSA velocity (PSAV), can be used to assist in
differentiating between men with cancer from those with benign
disease (Carter et al, 1992; Berger et al, 2005). Monitoring PSA
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over time could also improve the sensitivity of screening. It is also
possible that PSAV could distinguish between men who might
have advanced or aggressive disease that would require definitive
treatment thus avoiding overdiagnosis and overtreatment (Carter
et al, 2006; Carter et al, 2007).
However, the utility of PSAV in PrCa decision-making
has been called into question. In particular, while PSAV may
be predictive of biopsy outcome in univariate analyses, it
has not been shown to improve the predictiveness of biopsy
outcome over the absolute value of PSA (Roobol et al, 2004;
Vickers et al, 2011; Loughlin, 2014). Although some studies
have suggested that PSAV can be used to identify men with
aggressive disease, these did not investigate whether calculation
of PSAV provided additional information than the most
recent PSA value (Carter et al, 1992; D’Amico et al, 2004;
D’Amico et al, 2005). PSA and PSAV are highly correlated, and
this may explain why PSAV does not add predictive value
(Vickers et al, 2011). As a result of these considerations, PSAV
has been removed from all major guidelines concerning the
detection of prostate cancer.
It is currently unknown whether PSAV provides more
information, beyond PSA absolute value, among a cohort of men
considered to be at increased genetic risk of PrCa and aggressive
disease. The IMPACT study (Identification of Men with a
genetic predisposition to ProstAte Cancer: Targeted screening in
men at higher genetic risk and controls; www.impact-study.co.uk)
is an international multi-centre study evaluating the role of
targeted PSA screening in men with a BRCA1 or BRCA2
mutation and was established in 2005 (Bancroft et al, 2014). To
date, B3000 men have been recruited from 20 countries
across the world. Men are followed up with annual (or biannual
in the Dutch cohort) PSA screening for a minimum of 5 years
within the study and this has produced a wealth of PSA results and
follow-up data over time. The primary end-point of the IMPACT
study is to determine the incidence, stage and pathology of screen-
detected prostate cancer in the study population; a secondary end-
point is to determine a profile of PSA level and its predictive value
for the development of prostate cancer in the study population.
The objective of the present study was to determine whether
PSA values and/or PSAV were associated with PrCa and aggressive
tumours among men at increased risk enrolled in the IMPACT
trial.
MATERIALS AND METHODS
Patient selection. The design and eligibility criteria for the
IMPACT study have been described elsewhere (Mitra et al, 2008;
Bancroft et al, 2014). The protocol was approved by the West-
Midlands Research and Ethics Committee in the UK (reference 05/
MRE07/25), and subsequently by each participating institution’s
local committee. Briefly, men aged between 40 and 69 were
recruited from families with a known pathogenic germline BRCA1
or BRCA2 mutation. Men were invited to enrol if they had tested
positive (carriers) or negative for the familial mutation (BRCA1/2
non-carriers), or if they were at 50% risk of inheriting a mutation
but had not yet undergone predictive genetic testing. All
participants provide written consent. Men with PrCa or with a
prior diagnosis of another cancer with a prognosis of o5 years
were excluded. In the Dutch centres, men were also excluded if
they had PSA screening prior to study entry.
According to the IMPACT study design, men underwent annual
PSA screening and those with a PSA 43.0 ngml l were referred
for a 10- or 12-core transrectal ultrasound guided (TRUS) biopsy
based on institutional clinic practices. Men with a PSA43.0 ng/ml
and a negative biopsy continue annual screening, with a repeat
biopsy recommended when PSA increased by 450%. Men were
also referred for biopsy if they had a PSAp3.0 ngml l but clinical
suspicion (e.g., abnormal digital rectal examination or clinical
symptoms). After 5 years in the study, men at a subset of centres
were also offered an elective biopsy.
PSA readings in the study are validated in a central laboratory to
exclude inter-site variations. The results found a Spearman’s
agreement of 0.95 between study sites (Bancroft et al, 2014).
Statistical considerations. PSA velocity (PSAV) has been used as a
marker to inform decisions about biopsy or about the timing of the
next PSA screen. With respect to the former, we considered that a
physician had the most recent PSA measurements available. Our
study question was therefore whether adding PSAV to this data
point improves prediction of presence of PrCa at biopsy. As
elevated PSA is the primary indication in routine clinical practice,
our main analysis was restricted to men who had any PSA
X3.0 ngml l prior to biopsy. A sensitivity analysis was conducted
including all men who underwent biopsy. We created logistic
regression models, adjusted for last PSA measurement and age, for
the outcomes of any grade and high-grade cancer. PSAV was
calculated using three methods: arithmetic equation of change in
PSA over time; linear regression; rate of PSA change using first and
last values only. We also used cubic splines with knots at the
tertiles to test for non-linearity in PSA and in PSAV.
To investigate whether the effect of PSAV on predicting biopsy
outcome differed based on BRCA status, we included an interaction
term between PSAV and BRCA status (BRCA1 or BRCA2 carriers
vs BRCA non-carrier patients, and BRCA2 carriers vs BRCA1 and
BRCA non-carrier patients). Due to a limited number of events,
this analysis was performed only for the outcome of any cancer on
biopsy. This analysis included 13 cancers diagnosed among 55
BRCA1 carriers and 23 cancers among 65 BRCA2 carriers.
To determine whether PSAV could aid decisions about screen-
ing frequency, e.g., whether a man with a high PSAV should
receive a subsequent PSA test at a shorter interval than a man with
low PSAV, we assessed whether PSAV was associated with having
a future PSA 43.0 ngml l. As a minimum of three PSA
measurements are required for accurate estimation of PSAV, we
created Cox proportional hazards models for the time from the
first PSA measurement to the patient’s third PSA measurement
43.0 ngml l. Four models were then created: one including the
third PSA measurement only, and the others including both the
third PSA measurement and each of the three methodologies for
calculating PSAV. Men who had a PSA 43.0 ngml l within the
first three PSA measurements were excluded from this analysis. A
total of 1086 men were included.
We planned to first evaluate the independent statistical
significance of PSAV in models that also included absolute PSA
level. If significant, we planned to estimate the improvement in
concordance index afforded by PSAV after 10-fold cross-valida-
tion. All analyses were conducted using Stata 13.0 (Stata Corp.,
College Station, TX, USA).
RESULTS
Of the 2942 men recruited to the IMPACT study, 1654 men had
three or more PSA measurements and appropriate clinical follow-
up to be included in the analyses (Figure 1). Table 1 shows the
demographic, PSA and biopsy grade characteristics of the analysis
cohorts. The cohort of 1654 men consisted of 510 BRCA1mutation
carriers, 584 BRCA2 mutation carriers, 260 BRCA1 non-carriers
and 288 BRCA2 non-carriers. Two men carried both a BRCA1 and
BRCA2 mutation (included in the BRCA2 group for genetic sub-
analysis) and 10 had not yet had a predictive test for the BRCA
mutation in their family (excluded from genetic sub-analysis). In
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this cohort, 174 men underwent prostate biopsy, with 45 men
having any grade cancer of whom 21 having Gleason score 7 or
higher (high-grade) cancer. Among men who had any PSA
43.0 ngml l, 40 had any grade of whom 20 had high-grade
cancer.
The median age at the first PSA of BRCA2 carriers was
significantly younger than both BRCA1 carriers and non-carriers
(51 vs 53 vs 54 years, respectively, Po0.0001). Overall, BRCA2 and
BRCA1 carriers had significantly lower first PSA values than non-
carriers (0.80 vs 0.80 vs 0.89 ngml l; P¼ 0.022; however, overall
there was no statistically significant difference in the median PSAV
between the BRCA2, BRCA1 and non-carrier groups (P¼ 0.8).
The median age at first PSA reading of men diagnosed with
cancer was higher than that of men without cancer (60 vs 53 years,
U¼ 22069, z¼  5.24, Po0.001). The median most recent PSA
(i.e., PSA at diagnosis for cancer cases) was significantly higher for
those with cancer compared with those without cancer (3.70 vs
0.90 ngml l) U¼ 8564, z¼  9.34, Po0.001). The median PSAV
was significantly higher for those with cancer vs those without
cancer (medians: 0.56 vs 0.02 ng/ml/yr, U¼ 9641, z¼  9.012,
Po0.001). Of those diagnosed with cancer, there was no significant
difference between the proportion of BRCA2 carriers with a PSAV
(calculated by linear regression)40.35 ngml l per year compared
with BRCA1 carriers and non-carrier controls (78.3 vs 61.5 vs
53.8%, p0.28).
We next assessed whether adding PSAV to the most recent PSA
measurement would improve the ability to determine which men
should undergo biopsy. Using cubic splines, we investigated and
found no evidence of non-linearity in PSA or in PSAV. Among
men with any PSA measurements 43.0 ng/ml, PSAV was not
significantly associated with either any grade or high-grade cancer
after adjusting for most recent PSA measurement (Table 2). We
repeated these analyses including all men who were biopsied, and
found that PSAV was not statistically significant in any of the
models (Table 3).
Additionally, we assessed whether PSAV affected the prediction
of PrCa at biopsy differently based on BRCA status. When
comparing BRCA1 and BRCA2 carriers to BRCA1/2 non-carriers,
we found a significant interaction between BRCA status and the
last PSA before biopsy (P¼ 0.031), however there was no evidence
of an interaction between BRCA status and PSAV (Table 4).
However, when comparing BRCA2 carriers to BRCA1 carriers and
BRCA1/2 non-carriers, we found evidence of interactions between
BRCA2 status and last PSA before biopsy (P¼ 0.078) and
2942 men in
the IMPACT
study
9883 total PSA
readings
Number of men
undergoing
biopsy: 209
Number of
men with 3
PSA readings:
1654
Number of
men with <3
PSA readings:
1288
Biopsy
outcome:
Cancer: 87
No Biopsy: 1480
Number of men
undergoing
biopsy: 174
No Biopsy: 1079 Biopsyoutcome:
Benign: 122
Biopsy
outcome:
Benign: 129
Biopsy
outcome:
Cancer: 45
Biopsies:
Total Cancers:
132
Total Benign:
251
Figure 1. Consort diagram of study population. The two bolded cohorts were included for in-depth analysis, as they had 3 or more PSA values
available for analysis and underwent a prostate biopsy.
Table 1. Patient characteristics
Total cohort
N¼1654 BRCA2 N¼586
a BRCA1 N¼510 Non-carrier controls (BRCA1 and BRCA2
negative) N¼548
Age at first PSA test 53 (46, 60) 51 (45, 59) 53 (46, 60) 54 (48, 61)
Patient underwent biopsy 174 (11%) 65 (11%) 55 (11%) 54 (10%)
Prior negative biopsy 26 (1.6%) 8 (1.4%) 8 (1.6%) 10 (1.8%)
Biopsy Gleason score
p6 24 (14%) 11 (17%) 6 (11%) 7 (13%)
7 15 (8.6%) 6 (9.2%) 6 (11%) 3 (5.6%)
47 6 (3.4%) 5 (7.7%) 0 (0%) 1 (1.9%)
Negative biopsy 129 (74%) 43 (66%) 43 (78%) 43 (80%)
First PSA measurement (ngml1) 0.8 (0.5, 1.3) 0.80 (0.50, 1.20) 0.80 (0.50, 1.30) 0.89 (0.60, 1.40)
Last PSA measurement (ngml1) 0.9 (0.6, 1.6) 0.91 (0.59, 1.50) 0.88 (0.55, 1.70) 1.00 (0.60, 1.70)
Number of PSA tests before biopsy
3 503 (30%) 163 (28%) 158 (31%) 178 (32%)
4 328 (20%) 123 (21%) 108 (21%) 96 (18%)
5 474 (29%) 160 (27%) 135 (26%) 174 (32%)
6 156 (9.4%) 62 (11%) 50 (10%) 44 (8.0%)
7 108 (6.5%) 36 (6.1%) 38 (7.5%) 34 (6.2%)
8 or more 85 (5.1%) 42 (7.2%) 21 (4.1%) 22 (4.0%)
Data are reported as median (interquartile range) or frequency (%).
aIncludes 2 men who had both a BRCA1 and a BRCA2 mutation.
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significant interactions between BRCA2 status and PSAV calcu-
lated using the arithmetic equation and linear regression (P¼ 0.024
and P¼ 0.049 respectively, Table 4).
Based on these interactions, we performed subgroup analyses by
BRCA2 status. All models were adjusted for age at biopsy and last
PSA before biopsy. Due to a limited number of events (26 cancers
in BRCA2 non-carriers and 23 in BRCA2 carriers), these models
were somewhat overfit. No evidence of an association between PSA
and any grade cancer or PSAV and any grade cancer was seen in
BRCA2 carriers or non-carriers, likely due to the strong correlation
between PSA and PSAV (Table 5).
We then investigated whether PSAV was associated with time to
PSA X3.0 ngml l. Using Cox proportional hazards models, we
found no evidence of an association between PSAV and time from
the third PSA measurement to PSA X3.0 ngml l. Out of 1533
men who did not have a PSA X3.0 ngml l within the first three
PSA tests, there were 28 who had a PSA X3.0 ngml l within 1
year, 50 within 2 years and 62 within 3 years.
DISCUSSION
This is the first study to show that there are differences in PSA
values among men with different genetic backgrounds. These PSA
differences could be used to identify those men considered to be at
high genetic risk of more aggressive disease. However, when
evaluated with absolute PSA values, PSAV did not appear to
provide additional information for BRCA1 or BRCA2 carriers.
A major problem of PSA screening is that, in attempting to
detect clinically significant disease, it is inevitable that indolent
disease will also be detected leading to overdiagnosis. However,
early diagnosis and identification of men with high-risk disease is
important to prevent mortality from PrCa. This might be
particularly essential in light of recent publications indicating that
men with a BRCA1 or BRCA2 mutation are at risk of more
aggressive disease (Castro et al, 2013; Castro et al, 2015), early
identification of those with clinically significant disease will be
imperative. In view of the controversy about the role of PSAV in
prostate screening in the general population, it was important to
assess its role in BRCA1 and BRCA2 carriers and whether it added
to the ability to detect clinically significant disease.
In this analysis of the IMPACT study cohort, we found BRCA2
carriers on average to be screened at a relatively young age. This
may account for lower overall PSA values for BRCA2 carriers in
this analysis compared to non-carrier controls. However, there
were no differences in median PSAV between carriers and non-
carriers. Given the possibility that higher PSAV may associate with
aggressive PrCa (D’Amico et al, 2004; D’Amico et al, 2005), we
would expect BRCA2 carriers who are at risk of aggressive disease
would exhibit higher PSAVs (Castro et al, 2013; Castro et al, 2015).
BRCA2 carriers in this group may be too young to demonstrate this
trend at this point of follow up.
A single PSA reading over 3 ngml l was applied to guide
biopsy decisions according to the IMPACT protocol, as well as if
there was clinical suspicion on digital rectal examination or clinical
symptoms. PSAV was not a good indicator in this analysis for
distinguishing between those with any grade cancer and high-grade
cancer when men were biopsied for either indication. It is possible
that PSAV could be a good predictor of high-grade disease in men
who had PSA valuesp2 ngml l (Kitagawa et al, 2014). However,
due to the protocol’s 3 ng/ml PSA threshold for prostate biopsy, we
were limited in the number of cancers diagnosed when PSA was
p2 ngml l. Further follow up will be required to assess when
additional cancers are diagnosed. As part of the IMPACT trial,
there is an optional end of study biopsy regardless of PSA. This
may help delineate PSAV among men diagnosed with PrCa with
low PSA values (Carter et al, 1992; Kitagawa et al, 2014).
Table 2.Models for any grade and high-grade cancers among
men with any PSA measurement X3.0 ng/ml, N¼116
Any grade cancer High grade cancer
OR
95%
CI
P
value
OR
95%
CI
P value
Age at biopsy 1.05 0.99,
1.12
0.13 1.08 0.99,
1.19
0.073
Last PSA measurement
before biopsy
1.05 0.89,
1.23
0.6 1.26 1.04,
1.52
0.017*
Age at biopsy 1.05 0.98,
1.12
0.14 1.09 0.99,
1.19
0.065
Last PSA measurement
before biopsy
1.08 0.89,
1.30
0.4 1.20 0.97,
1.49
0.10
PSA velocity (arithmetic
equation)
0.91 0.69,
1.21
0.5 1.20 0.81,
1.76
0.4
Age at biopsy 1.06 0.99,
1.13
0.080 1.10 1.00,
1.20
0.047*
Last PSA measurement
before biopsy
0.93 0.75,
1.17
0.5 1.12 0.88,
1.44
0.3
PSA velocity (linear
regression)
1.92 0.92,
4.00
0.080 2.07 0.93,
4.61
0.076
Age at biopsy 1.06 0.99,
1.13
0.073 1.10 1.00,
1.21
0.042*
Last PSA measurement
before biopsy
0.91 0.72,
1.16
0.4 1.09 0.83,
1.42
0.5
PSA velocity (first and
last value)
2.01 0.94,
4.29
0.073 2.25 0.96,
5.28
0.063
Abbreviations: CI¼ confidence interval; PSA¼prostate-specific antigen. All models were
adjusted for age at biopsy and the last PSA measurement before biopsy. *Statistically
significant.
Table 3.Models for any grade and high grade cancers among
all men undergoing biopsy, N¼174
Any grade cancer High grade cancer
OR
95%
CI
P
value
OR
95%
CI
P value
Age at biopsy 1.05 1.00,
1.11
0.051 1.08 1.00,
1.18
0.056
Last PSA measurement
before biopsy
1.13 1.00,
1.28
0.058 1.35 1.14,
1.59
0.001*
Age at biopsy 1.05 1.00,
1.10
0.064 1.09 1.00,
1.18
0.050
Last PSA measurement
before biopsy
1.17 1.01,
1.36
0.041* 1.29 1.06,
1.57
0.010*
PSA velocity (arithmetic
equation)
0.88 0.67,
1.17
0.4 1.19 0.79,
1.78
0.4
Age at biopsy 1.06 1.00,
1.11
0.033* 1.10 1.01,
1.19
0.036*
Last PSA measurement
before biopsy
1.01 0.84,
1.22
0.9 1.19 0.95,
1.50
0.14
PSA velocity (linear
regression)
1.85 0.92,
3.71
0.085 2.09 0.95,
4.62
0.068
Age at biopsy 1.06 1.01,
1.11
0.030* 1.10 1.01,
1.20
0.033*
Last PSA measurement
before biopsy
1.00 0.82,
1.22
40.9 1.16 0.90,
1.49
0.2
PSA velocity (first and
last value)
1.90 0.93,
3.89
0.080 2.24 0.97,
5.20
0.059
Abbreviations: CI¼ confidence interval; PSA¼prostate-specific antigen. All models were
adjusted for age at biopsy and the last PSA measurement before biopsy. *Statistically
significant.
PSA velocity in IMPACT Study BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.429 269
A strength of this study is the unique patient cohort of men with
a genetic predisposition to PrCa, in particular BRCA2 carriers who
are predisposed to aggressive PrCas (Mitra et al, 2008; Narod et al,
2008; Castro et al, 2013; Castro et al, 2015). Within the group of
BRCA2 carriers, PSAV proved predictive of any grade cancer,
however, given the low number of cancers diagnosed overall it was
not possible to assess whether PSAV was associated with high
grade cancer and BRCA2 status. A high PSAV in an individual with
a BRCA2 mutation could be used as an indicator of presence of
PrCa and therefore as an indication for prostate biopsy. This model
could lead to diagnosis of lower grade cancers in BRCA2 carriers. It
may lead to better prognosis for men at risk for more aggressive
disease and better disease-free survival when treated early.
Although there are no definitive treatment recommendations for
men with BRCA2 mutations when found to be diagnosed with low
grade cancers, their risk for aggressive disease may spur them to
follow a more active treatment plan such as radical prostatectomy
vs external-beam radiation therapy or active surveillance (Bratt and
Loman, 2015; Castro et al, 2015).
One major limitation of this analysis is the relatively small
number of men in the study who had undergone diagnostic
prostate biopsy. End of study biopsies are not mandated and the
true incidence of PrCa is unknown in this population. As more
men progress through the IMPACT screening study, undergo
prostate biopsy and follow-up time increases, the findings from
this analysis can be explored and validated. At this point, the
results from this analysis did not justify modifying the study
algorithm to include a PSAV calculation.
In the general population, PSAV is not part of any major
screening guideline. We also did not find PSAV to be an
independent prognostic factor in BRCA1 or BRCA2 mutation
carriers and therefore for screening an absolute PSA cut-off value
should preferably be used.
CONCLUSION
PSA is more strongly predictive of PrCa in BRCA carriers than
BRCA non-carriers. We did not find evidence that PSAV aids to
decision making for either indicating biopsy or frequency of
follow-up testing in BRCA carriers, but further follow-up is
required for more definitive conclusions.
Table 4. Models for any grade cancer based on BRCA status
(BRCA positive carriers vs BRCA negative non-carriers) and
BRCA2 status (BRCA2 positive vs BRCA1 positive and BRCA
negative)
BRCA1 and BRCA2
vs BRCA
non-carriers
BRCA2 vs BRCA1
and BRCA
non-carriers
OR
95%
CI
P
value
OR
95%
CI
P value
Age at biopsy 1.07 1.01,
1.13
0.017* 1.06 1.01,
1.12
0.022*
Last PSA measurement
before biopsy
0.87 0.65,
1.16
0.3 0.99 0.81,
1.20
0.9
BRCA1 or BRCA2
Positive
0.40 0.10,
1.67
0.2 0.74 0.21,
2.65
0.6
Interaction between
last PSA measurement
and BRCAþ
1.44 1.03,
2.02
0.031* 1.28 0.97,
1.69
0.078
Age at biopsy 1.06 1.00,
1.12
0.034* 1.06 1.01,
1.12
0.025*
Last PSA measurement
before biopsy
1.14 0.97,
1.35
0.10 1.06 0.89,
1.27
0.5
PSA velocity using all
PSAs (arithmetic
equation)
0.77 0.51,
1.16
0.2 0.72 0.49,
1.08
0.11
BRCA1 or BRCA2
Positive
1.54 0.66,
3.61
0.3 1.07 0.43,
2.67
0.9
Interaction between
PSAV and BRCAþ
1.31 0.74,
2.34
0.4 2.63 1.13,
6.12
0.024*
Age at biopsy 1.07 1.01,
1.13
0.014* 1.07 1.02,
1.13
0.010*
Last PSA measurement
before biopsy
0.97 0.81,
1.18
0.8 0.93 0.75,
1.15
0.5
PSA velocity using all
PSAs (linear regression)
1.19 0.49,
2.89
0.7 1.46 0.69,
3.11
0.3
BRCA1 or BRCA2
Positive
0.99 0.37,
2.68
40.9 0.93 0.34,
2.52
0.9
Interaction between
PSAV and BRCAþ
2.26 0.74,
6.90
0.2 3.26 1.01,
10.54
0.049*
Age at biopsy 1.07 1.01,
1.13
0.013* 1.07 1.02,
1.13
0.009*
Last PSA measurement
before biopsy
0.97 0.79,
1.18
0.7 0.92 0.74,
1.16
0.5
PSA velocity using all
PSAs (first and last
value)
1.24 0.50,
3.07
0.6 1.48 0.68,
3.18
0.3
BRCA1 or BRCA2
Positive
1.01 0.37,
2.74
40.9 0.92 0.34,
2.51
0.9
Interaction between
PSAV and BRCAþ
2.08 0.70,
6.20
0.2 2.96 0.97,
9.02
0.056
Abbreviations: CI¼ confidence interval; PSA¼prostate-specific antigen. All models were
adjusted for age at biopsy, last PSA measurement before biopsy, BRCA status and the
interaction between PSA or PSA velocity and BRCA status. *Statistically significant.
Table 5. Models for any grade cancer by BRCA2 status
(BRCA2 carriers vs BRCA1 carriers and BRCA1/2 non-carriers)
BRCA2 Carriers
(N¼65)
BRCA2 Non-carriers
(N¼109)
OR
95%
CI
P
value
OR
95%
CI
P value
Age at biopsy 1.02 0.95,
1.10
0.6 1.10 1.02,
1.19
0.011*
Last PSA measurement
before biopsy
1.27 1.05,
1.54
0.013* 0.97 0.79,
1.19
0.8
Age at biopsy 1.03 0.95,
1.11
0.5 1.10 1.02,
1.19
0.017*
Last PSA measurement
before biopsy
1.12 0.81,
1.55
0.5 1.03 0.83,
1.27
0.8
PSA velocity (arithmetic
equation)
1.61 0.57,
4.55
0.4 0.74 0.49,
1.11
0.14
Age at biopsy 1.04 0.96,
1.12
0.4 1.11 1.02,
1.19
0.010*
Last PSA measurement
before biopsy
1.01 0.71,
1.44
40.9 0.90 0.68,
1.19
0.4
PSA velocity (linear
regression)
3.27 0.65,
16.38
0.15 1.56 0.66,
3.67
0.3
Age at biopsy 1.04 0.96,
1.12
0.4 1.11 1.02,
1.19
0.010*
Last PSA measurement
before biopsy
1.00 0.67,
1.49
40.9 0.89 0.67,
1.19
0.4
PSA velocity (first and
last value)
3.08 0.58,
16.42
0.2 1.55 0.66,
3.66
0.3
Abbreviations: CI¼ confidence interval; OR¼odds ratio; PSA¼prostate-specific antigen.
All models are adjusted for age at biopsy and last PSA measurement before biopsy.
*Statistically significant.
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